{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ulcerative+Colitis%2C+Active+Severe&page=4", "query": { "condition": "Ulcerative Colitis, Active Severe", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 121, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ulcerative+Colitis%2C+Active+Severe&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ulcerative+Colitis%2C+Active+Severe&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T20:21:38.723Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06257875", "title": "A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Lutikizumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2024-03-23", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 48, "location_summary": "Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06257875" }, { "nct_id": "NCT03482635", "title": "BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 98, "start_date": "2018-03-27", "completion_date": "2020-05-18", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 13, "location_summary": "Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03482635" }, { "nct_id": "NCT05570006", "title": "Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "ABBV-668", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-03-16", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 18, "location_summary": "Chula Vista, California • Maitland, Florida • Margate, Florida + 13 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Maitland", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05570006" }, { "nct_id": "NCT07845487", "title": "A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis (UC)", "Severe Ulcerative Colitis", "Moderate Ulcerative Colitis" ], "interventions": [ { "name": "PALI-2108", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Palisade Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 204, "start_date": "2026-08-28", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 30, "location_summary": "Sun City, Arizona • San Diego, California • Bristol, Connecticut + 27 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Bristol", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Des Plaines", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07845487" }, { "nct_id": "NCT01900574", "title": "A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Golimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 35, "start_date": "2013-08-09", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2023-05-11", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01900574" }, { "nct_id": "NCT04987307", "title": "Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Efavaleukin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 221, "start_date": "2022-01-31", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 63, "location_summary": "Dothan, Alabama • Homewood, Alabama • Mesa, Arizona + 57 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04987307" }, { "nct_id": "NCT04985968", "title": "The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Cobitolimod 250 mg", "type": "DRUG" }, { "name": "Cobitolimod 500 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InDex Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2021-11-24", "completion_date": "2023-12-20", "has_results": false, "last_update_posted_date": "2023-12-27", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 25, "location_summary": "Granada Hills, California • Mission Viejo, California • Rancho Cucamonga, California + 17 more", "locations": [ { "city": "Granada Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985968" }, { "nct_id": "NCT05507203", "title": "ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "ABX464", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abivax S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 639, "start_date": "2022-11-16", "completion_date": "2025-06-25", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 54, "location_summary": "Dothan, Alabama • Guntersville, Alabama • Homewood, Alabama + 45 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05507203" }, { "nct_id": "NCT02914522", "title": "Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "PTM filgotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1351, "start_date": "2016-11-14", "completion_date": "2020-03-31", "has_results": true, "last_update_posted_date": "2021-04-21", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 61, "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02914522" }, { "nct_id": "NCT03996369", "title": "Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrasimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arena Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 354, "start_date": "2020-09-15", "completion_date": "2021-12-07", "has_results": true, "last_update_posted_date": "2022-12-21", "last_synced_at": "2026-10-05T20:21:38.723Z", "location_count": 62, "location_summary": "Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03996369" } ] }